Abstract:
PURPOSE: A composition containing xanthohumol is provided to promote differentiation of osteoclast and to treat bone diseases. CONSTITUTION: A composition for preventing or treating osteoclast differentiation contains xanthohumol as an active ingredient. The composition contains xanthohumol and bone resorption inhibitor as an active ingredient. The bone absorption inhibitor is bisphosphonate, estrogen, calcitonin, vitamin D, calcium, fluoride, anabolic steroid or parathyroid hormone. A health functional food for preventing or treating osteoporosis contains xanthohumol as an active ingredient. The health functional food includes drink, meat, sausage, bread, candy, snack, noodle, ice cream, soup, isotonic drink, alcohol beverage, or vitamin complex.
Abstract:
PURPOSE: A composition containing purple sweet potato extract is provided to suppress fibrosis of rat liver cells and to prevent and treat fibrosis. CONSTITUTION: A pharmaceutical composition for preventing or treating hepatic fibrosis contains extract as an active ingredient, prepared by extracting purple sweet potato using 50-100% ethanol solution. A health food for preventing or treating hepatic fibrosis contains the ethanol solution as an active ingredient. The health food is manufactured in the form of a daily product including drink, meats, sausage, candy, bread, noodle, and ice cream.
Abstract:
PURPOSE: A composition for preventing or treating breast cancer and ovarian cancer, comprising mollugin is provided to have excellent effect of killing cancer cells. CONSTITUTION: A composition for preventing or treating breast cancer and ovarian cancer comprises mollugin of chemical formula 1. The breast cancer or ovarian cancer is a cancer that the gene of human epidermal growth factor receptor 2 (HER2) is overexpressed. The composition suppresses HER2/Akt/sterol regulatory element binding proteins (SREBPs). A pharmaceutical composition for preventing or treating breast cancer and ovarian cancer comprises the mollugin and a pharmaceutical exipient. The mollugin in the pharmaceutical composition is comprised in a ratio of 0.001-99.9 wt%.
Abstract:
PURPOSE: A pharmaceutical composition containing 3-caffeoyl-4-dihydrocaffeoyl quinic acid(CDCQ) is provided to suppress cell basal lamina digesting enzyme MMP-2 and MMP-9 activities and prevent cancer cell metastasis. CONSTITUTION: A pharmaceutical composition for suppressing cancer metastasis contains 3-caffeoyl-4-dihydrocaffeoylquinic acid. The composition suppresses activity of MMP-2(matrix metalloprotease-2) or MMP-9(matrix metalloprotease-9). A health food for preventing metastasis contains 3-caffeoyl-4-dihydrocaffeoylquinic acid. A composition for anticancer and metastasis suppression contains 3-caffeoyl-4-dihydrocaffeoylquinic acid and anticancer agent as an active ingredient. The anticancer agent includes busulfan, chlorambucil, cyclophosphamide, melphalan, nitrogen mustard, BCNU(1,3-bis (2-chloroethyl)-1 nitrosourea), CCNU(l-(2-Chloroethyl)-3-Cyclohexyl-1-Nitrosourea), MeCCNU(1-(2-chloroethyl)-3-(4-methyl-cyclohexyl)-1-nitrosourea), cisplatin, ifosfamide, cytarabine, fluouracil(5-FU), mercaptopurine(6-MP), methotrexate(MTX), actinomycin-D, bleomycin, daunorubicin, adriamycin, mitomycin-C, vinblastine, vincristine(oncovin), vindesine, VP-16(etoposide), L-aspraginase, dacarbazine(DTIC) or hydroxyurea.